On December 19, 2019 IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company" or "IntelGenx") is reported that it has filed a preliminary short form prospectus (the "Prospectus") with respect to an offering (the "Offering") of units ("Units") for a minimum of Cdn$4,000,000 and a maximum of Cdn$10,000,000 aggregate gross proceeds (Press release, IntelGenx, DEC 19, 2019, View Source [SID1234552506]). Each Unit will consist of one share (an "Offered Share") of the common stock of the Company ("Common Stock") and one half of one common stock purchase warrant (each whole common stock purchase warrant, a "Warrant"). Each Warrant will entitle the holder to purchase one share of Common Stock (a "Warrant Share"). Concurrently with the filing of the Prospectus, the Corporation has filed a registration statement on Form S-1 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") to register the Units and the Warrant Shares.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the "Agent") in the provinces of British Columbia, Alberta, Manitoba and Ontario. Final pricing of the Units (the "Offering Price"), the Warrant exercise price and term, and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering.

The Company has granted to the Agent an option to increase the size of the Offering by up to 15%, exercisable in whole or in part at any time for a period of 30 days after and including the closing date of the Offering.

The net proceeds from the Offering will be used for the Company’s Phase 2A Montelukast Study, general working capital requirements, and, depending on the size of the offering, expansion of the Company’s manufacturing facility.

The Company will apply to list the Offered Shares and the Warrant Shares underlying the Units on the TSX Venture Exchange (the "TSXV"). There is no established trading market for the Warrants and IntelGenx does not expect a market to develop. A copy of the Prospectus is available under the Corporation’s profile at www.sedar.com and a copy of the Registration Statement can be obtained from the SEC’s website at www.sec.gov or by request to Echelon Wealth Partners Inc. at [email protected]. The Offering is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSXV and the SEC declaring the Registration Statement effective.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.